Kala Pharmaceuticals Submits Investigational New Drug Application For Kpi-012 For Treatment Of Persistent Corneal Epithelial Defect
Kala Pharmaceuticals Inc 
KALA:
KALA PHARMACEUTICALS ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG APPLICATION FOR KPI-012 FOR THE TREATMENT OF PERSISTENT CORNEAL EPITHELIAL DEFECT
CASH RUNWAY EXTENDED INTO 1Q 2025
ON-TRACK TO INITIATE PHASE 2B TRIAL IN 4Q 2022, WITH TOPLINE DATA EXPECTED IN 1Q 2024